A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

The Global Generic Drugs Market achieved a valuation of $487.21 Billion in 2024 and is anticipated to exceed $898 Billion by ...

This is the molecule behind Novo Nordisk's white-hot ... It's also gearing up to sell biosimilars of Novo Nordisk diabetes treatment liraglutide. Investors plowed into Hims & Hers stock that ...

The reason Lilly is worth so much in the market's eyes is down to one drug molecule, tirzepatide ... even further by adding access to generic liraglutide and branded tirzepatide through our ...